Program
Conjugate
Also written as “Adsorbed Acellular Pertussis (3-Component) Diphtheria-Tetanus-Pertussis-Haemophilus influenzae type b (Conjugate)-Meningococcal Group ACYW135 (Conjugate) Combined Vaccine (DTcP-Hib-MCV4)” and “Meningococcal Group ACYW135 (Conjugate) (MCV4)”.
Its studies are mostly in Diphtheria, led by CanSino Biologics.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| CanSino Biologics | 11 open or running | phase 1since Sep 25, 2025 | Sep 25, 2025 | Feb 2029phase 1 · NCT07203755 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Feb 29, 2024Named conjugateINNProposed as its International Nonproprietary Name in WHO's List 130
- Sep 25, 2025First study: phase 1 study in DiphtheriaFirst studyNCT07203755 · 260 planned · China
Ahead
- Feb 2029Primary completion: phase 1 study in DiphtheriaNCT07203755
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07203755Diphtheria · China | 1 | Recruiting | Feb 2029 | 260 |
How it is read
Names in the registry
- “Adsorbed Acellular Pertussis (3-Component) Diphtheria-Tetanus-Pertussis-Haemophilus influenzae type b (Conjugate)-Meningococcal Group ACYW135 (Conjugate) Combined Vaccine (DTcP-Hib-MCV4)”, 1 entry
- “Meningococcal Group ACYW135 (Conjugate) (MCV4)”, 1 entry
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.